Literature DB >> 9633021

Peritoneal fluid levels of immunoreactive corticotropin-releasing factor (CRF) and CRF-binding protein (CRF-BP) in healthy and endometriosic women.

P Florio1, M Busacca, M Vignali, P Viganò, R J Woods, P J Lowry, A R Genazzani, S Luisi, M Santuz, F Petraglia.   

Abstract

Corticotropin-releasing factor (CRF) is a 41-amino acid neurohormone involved in the neuroendocrine response to stress, also playing a role in cell-mediated immune functions and in inflammation. In the light of recent evidence showing an association between endometriosis and altered cellular immunity factors, the present study investigates immunoreactive (ir) CRF in the peritoneal fluid of healthy women, and in patients with pelvic adhesions and endometriosis. In addition, peritoneal fluid concentrations of CRF-binding protein (CRF-BP), a 37-kDA protein of 322 amino acids able to modulate central and peripheral CRF functions, were evaluated. Peritoneal fluid samples (n = 35) were collected from healthy women (n = 12), from patients with intrapelvic adhesions (n = 8), and from women with endometriosis (n = 15). In the control group a specimen of blood was collected. Peritoneal fluid and plasma CRF levels were measured by a two-site immunoradiometric assay (IRMA), and CRF-BP levels were measured by a specific radioimmunoassay (RIA). CRF and CRF-BP levels in peritoneal fluid were lower than plasma values, and independent of the phase of the menstrual cycle: in particular, in healthy women there was no significant difference between peritoneal fluid and plasma CRF-BP levels during two phases of the menstrual cycle. Peritoneal fluid levels of CRF and CRF-BP were similar in healthy patients and women with pelvic adhesions or with endometriosis, and when patients with adhesions or with endometriosis were considered as single group, no difference in CRF and CRF-BP levels was noted in comparison to the control group. In patients with endometriosis, no significant differences in peritoneal fluid CRF or CRF-BP levels were recorded, although in patients with stage 2 and stage 3 of the disease peritoneal fluid CRF-BP levels were higher than in healthy patients or in those with a lower grade of the disease. These results suggest that the peritoneal concentration of these hormones may reflect the circulating levels: the absence of any significative variations in peritoneal fluid CRF levels according to the degree of the endometriosis, suggests a limited role of CRF in the immunological changes related to the disease

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9633021     DOI: 10.1007/BF03347284

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  30 in total

1.  Characterization of corticotropin-releasing hormone binding protein in human plasma by chemical cross-linking and its binding during pregnancy.

Authors:  T Suda; M Iwashita; F Tozawa; T Ushiyama; N Tomori; T Sumitomo; Y Nakagami; H Demura; K Shizume
Journal:  J Clin Endocrinol Metab       Date:  1988-12       Impact factor: 5.958

2.  Peritoneal fluid inhibin during the menstrual cycle.

Authors:  R Hemmings; T Falcone; R Billiar; T Tulandi
Journal:  Obstet Gynecol       Date:  1992-07       Impact factor: 7.661

3.  Monocyte-mediated enhancement of endometrial cell proliferation in women with endometriosis.

Authors:  D P Braun; A Muriana; H Gebel; C Rotman; N Rana; W P Dmowski
Journal:  Fertil Steril       Date:  1994-01       Impact factor: 7.329

4.  Corticotropin-releasing factor-binding protein is produced by human placenta and intrauterine tissues.

Authors:  F Petraglia; E Potter; V A Cameron; S Sutton; D P Behan; R J Woods; P E Sawchenko; P J Lowry; W Vale
Journal:  J Clin Endocrinol Metab       Date:  1993-10       Impact factor: 5.958

5.  Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo.

Authors:  K Karalis; H Sano; J Redwine; S Listwak; R L Wilder; G P Chrousos
Journal:  Science       Date:  1991-10-18       Impact factor: 47.728

6.  Association of human corticotropin-releasing hormone to its binding protein in blood may trigger clearance of the complex.

Authors:  R J Woods; A Grossman; P Saphier; K Kennedy; E Ur; D Behan; E Potter; W Vale; P J Lowry
Journal:  J Clin Endocrinol Metab       Date:  1994-01       Impact factor: 5.958

7.  Origin of peritoneal fluid in women: an ovarian exudation product.

Authors:  P R Koninckx; M Renaer; I A Brosens
Journal:  Br J Obstet Gynaecol       Date:  1980-03

8.  Corticotropin releasing hormone-binding protein (CRH-BP): plasma levels decrease during the third trimester of normal human pregnancy.

Authors:  E A Linton; A V Perkins; R J Woods; F Eben; C D Wolfe; D P Behan; E Potter; W W Vale; P J Lowry
Journal:  J Clin Endocrinol Metab       Date:  1993-01       Impact factor: 5.958

9.  Expression of intercellular adhesion molecule-1 (ICAM-1) on cultured human endometrial stromal cells and its role in the interaction with natural killers.

Authors:  P Viganó; R Pardi; B Magri; M Busacca; A M Di Blasio; M Vignali
Journal:  Am J Reprod Immunol       Date:  1994-10       Impact factor: 3.886

10.  Elevated levels of corticotrophin-releasing factor binding protein in the blood of patients suffering from arthritis and septicaemia and the presence of novel ligands in synovial fluid.

Authors:  R J Woods; J David; S Baigent; J Gibbins; P J Lowry
Journal:  Br J Rheumatol       Date:  1996-02
View more
  4 in total

Review 1.  Corticotropin-releasing factor family and its receptors: pro-inflammatory or anti-inflammatory targets in the periphery?

Authors:  Huayuan Zhu; Juejin Wang; Jianyong Li; Shengnan Li
Journal:  Inflamm Res       Date:  2011-04-08       Impact factor: 4.575

2.  Neuroendocrine circuitry and endometriosis: progesterone derivative dampens corticotropin-releasing hormone-induced inflammation by peritoneal cells in vitro.

Authors:  Nadja Tariverdian; Mirjam Rücke; Julia Szekeres-Bartho; Sandra M Blois; Eva F Karpf; Peter Sedlmayr; Burghard F Klapp; Heribert Kentenich; Friederike Siedentopf; Petra C Arck
Journal:  J Mol Med (Berl)       Date:  2009-11-08       Impact factor: 4.599

3.  Anxiety, coping skills and hypothalamus-pituitary-adrenal (HPA) axis in patients with endometriosis.

Authors:  Maria Quiñones; Rebecca Urrutia; Annelyn Torres-Reverón; Katy Vincent; Idhaliz Flores
Journal:  J Reprod Biol Health       Date:  2015-06-11

Review 4.  Neuroendocrine-immune disequilibrium and endometriosis: an interdisciplinary approach.

Authors:  Nadja Tariverdian; Theoharis C Theoharides; Friederike Siedentopf; Gabriela Gutiérrez; Udo Jeschke; Gabriel A Rabinovich; Sandra M Blois; Petra C Arck
Journal:  Semin Immunopathol       Date:  2007-06       Impact factor: 9.623

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.